The 2022 Society for Financial Studies Annual Meeting will take place at SFS Cavalcade North America at UNC at Chapel Hill in May 2022.
The program and registration for SFS Cavalcade North America 2022 are now available on the conference website. The Cavalcade will take place May 22-25 at the University of North Carolina at Chapel Hill.
Register by April 8 to pay the discounted registration fee. The registration fee is waived for PhD students.
The CSEF-RCFS Conference on Finance, Labor, and Inequality is now accepting submissions. Please see the Call for Papers. The conference, which features a dual submission option with RCFS, will take place in Capri from June 17-18, 2022. The RCFS sponsoring editor is Andrew Ellul. The submission deadline is April 3, 2022.
Regulatory capital requirements for banks have been a topic of heated discussions by academicians, bankers, and policy makers for decades. Central to these discussions is how costly requiring banks to fund themselves with more equity (rather than cheaper deposits) is and how these possible regulatory costs are transmitted to bank borrowers. In a recently published RCFS paper, “How Do Capital Requirements Affect Loan Rates? Evidence from High Volatility Commercial Real Estate,” David Glancy and Robert Kurtzman study these important questions. They specifically ask how capital requirements affect loan rates in the commercial real estate market. Their focus is high volatility commercial real estate loans, as the risk weights used in calculating regulatory capital for these types of loans recently increased. The authors exploit within-bank variation in capital requirements, allowing them to identify the effect on loan rates while controlling for bank-level confounders. Importantly, they find that a one-percentage-point increase in capital requirements raises loan rates by 8.5 basis points, with this estimate being the steady-state cost—rather than transition costs—of capital requirements as shown by the authors with further tests. The loan rate elasticity identified in this paper will be a key parameter in future research on the optimal level of capital requirements.
Spotlight by Isil Erel
Photos courtesy of David Glancy and Robert Kurtzman
“The Burden of the National Debt: Evidence from Mergers and Acquisitions” by Ruchith Dissanayake, Yanhui Wu, and Huizhong Zhang
“Social Change through Financial Innovation: Evidence from Donor-advised Funds” by Jillian Grennan
Recent estimates suggest that the cost of developing a single new drug in the biopharmaceutical sector is $2.6 billion, confirming the very large amounts of money that medical companies invest to develop a new treatment. Biomedical companies also face the risk of very low rates of success, not only due to the inherent scientific risk of developing new drugs, but also due to the risk of the Food and Drug Administration’s (FDA) regulatory approval process. The question that ought to be asked is what financial markets can do to promote more efficient risk sharing in the healthcare and drug development areas from which our societies can benefit. This is the question investigated by Adam Jørring, Andrew Lo, Tomas Philipson, Manita Singh, and Richard Thakor in their paper “Sharing R&D Risk in Healthcare via FDA Hedges.” They address the problem highlighted by many in the medical fields that investors are unwilling to provide financing due to these risks, resulting in a “funding gap” and underinvestment in biomedical R&D that causes many potentially valuable drugs either not being realized or not pursued beyond a certain stage. The authors propose a new form of financial instrument, FDA hedges, which allow biomedical R&D investors to share the pipeline risk associated with the FDA approval process with capital markets. Such instruments are shown to avoid the market failure that leads to an R&D “funding gap.” Using FDA approval data, the authors discuss the pricing of FDA hedges and mechanisms by which they can be traded and use novel panel dataset of FDA approval probabilities to explore the risks inherent in these contracts. The paper finds evidence that the risk associated with FDA hedges is mostly idiosyncratic, and argue that these instruments are appealing to both investors and issuers. Ultimately, FDA hedges should accelerate the development of new biomedical products by providing the necessary funding to support such risky projects, and will undoubtedly improve the health of countless patients. The significant social welfare implications are very clear for all of us.
Spotlight by Andrew Ellul
Photos courtesy of Adam Jørring, Andrew W. Lo, Tomas J. Philipson, Manita Singh, and Richard T. Thakor
First published December 10, 2021
The decisions for SFS Cavalcade North America 2022 have been sent. If you did not receive your decision, please contact us. We received 1433 submissions. The final program was highly selective, with an 9.4% acceptance rate.
If you selected dual submission with RAPS or RCFS, you will receive a separate decision email from the journal in the next few weeks.